期刊文献+

活菌制剂对2型糖尿病胃肠神经病变患者肠道菌群的影响 被引量:10

Effect of Living Bacteria Agent on Intestinal Flora in Type 2 Diabetes Mellitus Patients With Gastrointestinal Dysfunction
下载PDF
导出
摘要 目的研究2型糖尿病并胃肠功能紊乱患者服用双歧杆菌三联活菌胶囊治疗前后肠道双歧杆菌的变化。方法选取30例2型糖尿病并胃肠神经病变患者,给予双歧杆菌三联活菌胶囊口服,每次2粒,3次/d,治疗1个月,治疗前后收集粪便样品,提取样品中细菌DNA,根据双歧杆菌总菌的16S r RNA序列设计特异性引物,并应用实时荧光定量PCR技术对60份粪便样品中的双歧杆菌总菌进行定量检测。结果2型糖尿病并胃肠功能紊乱患者服用双歧杆菌三联活菌胶囊治疗后肠道双歧杆菌总菌数量较治疗前增加(P<0.05)。结论 2型糖尿病伴胃肠功能紊乱患者口服双歧杆菌活菌制剂能有效增加肠道双歧杆菌数量,改善胃肠道症状,双歧杆菌活菌制剂在2型糖尿病伴胃肠功能紊乱患者的治疗上有较好的运用前景。 Objective To study the influence of intestinal bifidobacteria on the type 2 diabetes patients with gastrointestinal dysfunction after taking bifid triple viable capsule.Methods Selecting 30 cases of type 2 diabetes patients with gastrointestinal dysfunction. Taking the bifid triple viable capsule(2 pieces each time,three times a day)for a month. Extracting the bacterial DNA of the fecal samples before and after the treatment. Designing the specific primer of bifidobacteria according to the bacterial 16SrRNA sequence. Quantitatively testing the total volume of bifidobacteria on the two different groups by applying the real-time PCR technology.Results After taking the bifid triple viable capsules,the total amount of bifidobacteria increased compared to the previous case(P〈0.05)for the type 2 diabetes patients with gastrointestinal dysfunction.Conclusion Bifid triple viable capsules help increase the amount of intestinal bifidobacterium effectively and improve the gastrointestinal symptoms. It is promising for type 2 diabetes patients with gastrointestinal dysfunction by using bifid triple viable capsules as the medical treatment.
出处 《中国卫生标准管理》 2016年第11期101-103,共3页 China Health Standard Management
基金 2型糖尿病伴或不伴胃肠神经功能紊乱患者肠道双歧杆菌的差异 云南省教育厅项目(2013Y294)
关键词 2型糖尿病 胃肠功能紊乱 双歧杆菌 双歧杆菌三联活菌胶囊 Type 2 diabetes Gastrointestinal disorders Bifidobacteria Bifidobacterium triple viable capsule
  • 相关文献

参考文献8

  • 1Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions [J ] . Neurogastroenterology& Motility, 2014, 26 ( 5 ) : 611-624.
  • 2任巧.2型糖尿病胃肠功能紊乱患者粪便菌群分析[J].临床医学,2013,33(3):54-55. 被引量:3
  • 3Gatopoulou A, Papanas N, Maltezos E, Diabetic gastrointestinalautonomic neuropathy: current status and new achievements for everyday clinical practice [J]. European journal of internal medicine, 2012, 23 (6) : 499-505.
  • 4Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gutmicroflora improve high-fat-diet-induced diabetes in mice through anaechanism associated with endotoxaemia[ J ]. Diabetologia, 2007, 50 (11) : 2374-2383.
  • 5Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance [J ] . Diabetes, 2007, 56 ( 7 ) : 1761-1772.
  • 6Chen JJ, Wang R., Li XF, et supplementation improved high- syndrome and promoted intestinal Experimental Biology and Medicine, al. Bifidobacteriumlongum fat-fed -induced metabolic Reg I gene expression [J] . 2011, 236 (7) : 823-831.
  • 7王雪萍,李军,陈建强.双歧杆菌三联活菌胶囊治疗糖尿病性胃肠功能紊乱60例疗效观察[J].医学理论与实践,2012,25(7):788-789. 被引量:13
  • 8张宜松,朱玉林,陈建国,王永莉,朱群.双歧杆菌三联活菌胶囊治疗2型糖尿病难治性腹泻的疗效观察[J].临床合理用药杂志,2014,7(13):74-74. 被引量:4

二级参考文献8

共引文献15

同被引文献88

引证文献10

二级引证文献118

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部